FAIRFIELD, N.J., May 24 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that Daniel Glassman, President and CEO, will participate in The Bank of America 2007 Health Care Conference at the Four Seasons Hotel in Las Vegas, Nevada. Mr. Glassman is scheduled to present on Wednesday, May 30, 2007, at 9:20 a.m. Pacific Daylight Time.
The presentation will be webcast live and can be accessed by visiting www.bradpharm.com and clicking on Calendar of Events or by clicking on http://www.veracast.com/webcasts/bas/healthcare07/id94103254.cfm.
It is recommended that listeners log on 15 minutes early in order to register. For those unable to participate during the live webcast, an archive version of the presentation will be available for 15 days beginning one hour after the live event and can be accessed at the same locations.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales which enables the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcement:
Bradley Pharmaceuticals will present at the FTN Midwest Securities Health Care Conference 2007, to be held at the Four Seasons Hotel in New York, NY, June 5, 2007.
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Safe Harbor for Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. Actual results may differ materially from those projected. These risks and uncertainties include those described from time to time in Bradley’s SEC filings, including its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Except as required by law, Bradley undertakes no obligation to publicly update any
forward-looking statement in this press release, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Cecelia C. Heer, Investor Relations, Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 252
Web site: http://www.bradpharm.com/
